Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-15 + Gemcitabine in Advanced Ovarian Cancer
NCT00051584Phase 2Terminated
- Sponsor
- Seagen Inc.
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SGN-15 in ovarian cancer, sponsored by Seagen Inc.. Status: terminated.
02
Drugs
SGN-15
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00051584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051584.